Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Declines By 80.3%

Aditxt, Inc. (NASDAQ:ADTXGet Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 40,700 shares, a decrease of 80.3% from the January 15th total of 206,800 shares. Approximately 2.1% of the shares of the company are sold short. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is presently 0.0 days.

Aditxt Price Performance

Shares of ADTX traded up $0.12 during mid-day trading on Monday, hitting $3.76. 9,339 shares of the company’s stock were exchanged, compared to its average volume of 173,996. Aditxt has a fifty-two week low of $3.27 and a fifty-two week high of $76.40. The business’s 50 day moving average is $4.54 and its two-hundred day moving average is $14.55.

Aditxt (NASDAQ:ADTXGet Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($48.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.99) by ($42.78). Aditxt had a negative net margin of 3,946.13% and a negative return on equity of 777.58%. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.25 million. On average, equities research analysts anticipate that Aditxt will post -80.82 earnings per share for the current year.

Hedge Funds Weigh In On Aditxt

Large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in Aditxt in the second quarter worth $71,000. Bank of New York Mellon Corp purchased a new position in Aditxt in the 3rd quarter valued at approximately $119,000. Armistice Capital LLC acquired a new position in Aditxt during the third quarter worth $350,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in Aditxt during the third quarter worth $423,000.

Aditxt Company Profile

(Get Free Report)

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.

Featured Stories

Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.